AIM ImmunoTech Inc. 8-K

What Happened
AIM ImmunoTech Inc. announced on May 19, 2026 (8-K) that it entered into Amendment #2 to its promissory note with Streeterville Capital, LLC. The amendment, dated May 18, 2026, extends the note's maturity from June 30, 2026 to June 30, 2027 and adds a $10,000 extension fee to the outstanding balance. The company reported the outstanding balance after the fee as $1,682,676.16. The amendment includes customary representations and warranties and is filed as Exhibit 10.1; a related press release was furnished as Exhibit 99.1.

Key Details

• Original promissory note: issued Feb 16, 2024 under a Note Purchase Agreement (original principal $3,301,250).
• Amendment date: May 18, 2026; new maturity date: June 30, 2027.
• Extension fee: $10,000, added to the note principal.
• Outstanding balance after fee: $1,682,676.16 (as of the amendment date). Lender: Streeterville Capital, LLC.

Why It Matters
The amendment defers AIM’s cash obligation on this loan by one year, shifting the repayment timetable from mid-2026 to mid-2027 and slightly increasing the recorded debt by the $10,000 fee. For investors, the filing confirms the company still carries a material outstanding debt (~$1.68M) and has secured more time to manage repayment or arrange refinancing. The amendment and press release are filed with the SEC for investor review.